– El segundo biosimilar de cáncer de mama EG1206A de EirGenix alcanza con éxito los objetivos del ensayo clínico de fase 1 TAIPEI, 3 de mayo de 2023 /PRNewswire/ — EirGenix, Inc. (6589.TT) anunció el 28 de abril que completó el ensayo clínico de fase 1 (EGC101) de su segundo biosimilar…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.